About Ryght
Ryght AI is a California-based, enterprise-grade generative AI platform purpose-built for the clinical research industry. It uses AI Site Twin technology — digital replicas of clinical trial sites worldwide — to automate and accelerate site selection, feasibility, activation, and patient enrollment for biopharma sponsors and CROs. Formerly known as Synthetica Bio, the company was founded in 2023 and serves major CROs and biopharma companies globally.
Company details
Funding
Total raised
$5.5M
Last stage
Seed
Investors
Founders
Simon Arkell
Australian-born two-time Olympian and serial entrepreneur focused on AI and healthcare technology. Co-founder of 7 venture-backed companies including Deep Lens, Predixion Software, and Versifi.
LinkedInJohn Crupi
Co-founder of Ryght AI, confirmed by Tracxn and Crunchbase.
Alex Dickinson
Co-founder and Chairman at Ryght AI. Previously Co-founder, Chair and CEO at ChromaCode (COVID XPrize winner), Helixis (acquired by Illumina), and Luxtera (acquired by Cisco).
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.